Millie Nelson

Millie Nelson

Millie Nelson

Editor, BioXconomy

Latest from Millie Nelson

Asia map on the globe

Eyes on Asia: Bain Capital buys MTPC, Merck & Co. halts HPV vax, and Illumina Eyes on Asia: Bain Capital buys MTPC, Merck & Co. halts HPV vax, and Illumina

byMillie Nelson

Feb 18, 2025

4 Min Read

Francesco De Rubertis, co-founder and partner at Medicxi (left) and Graziano Seghezzi, managing partner at Sofinnova Partners (right).

Sofinnova and Medicxi talk M&A, patent cliffs, and China Sofinnova and Medicxi talk M&A, patent cliffs, and China

byMillie Nelson

Feb 17, 2025

6 Min Read

All from Millie Nelson

Clock with the words timing is everything in red

Timing’s everything: Novartis pays $925m to buy Anthos and bring back Phase III mAb

Timing’s everything: Novartis pays $925m to buy Anthos and bring back Phase III mAb

byMillie Nelson, Editor

Steven fuller with a yellow background - Race in STEM founder and Director

Race in STEM: Countering the ugly truth of bias in life sciences

Race in STEM: Countering the ugly truth of bias in life sciences

byMillie Nelson, Editor

Alicia Secor, Female CEO of Atalanta Therapeutics

From research to development: Atalanta bags $97m to advance two RNAi therapies

From research to development: Atalanta bags $97m to advance two RNAi therapies

byMillie Nelson, Editor

‘Houston, we have a talent problem!’ TMC taps up next gen of biopharma experts

‘Houston, we have a talent problem!’ TMC taps up next gen of biopharma experts

byMillie Nelson, Editor

Asian currency

Eyes on Asia: Ascentage’s IPO, Arrivent & Lepu, Sanofi approval, and more

Eyes on Asia: Ascentage’s IPO, Arrivent & Lepu, Sanofi approval, and more

byMillie Nelson, Editor

Monika Paulė (Caszyme) and Dr Avencia Sánchez-Mejías (Integra Therapeutics) at BIO-Europe in Stockholm

Partnerships underpin the CRISPR revolution, says Caszyme CEO

Partnerships underpin the CRISPR revolution, says Caszyme CEO

byMillie Nelson, Editor

funding round on wooden blocks with dollars behind

The CAR-T promise: Umoja bags $100m in Series C financing

The CAR-T promise: Umoja bags $100m in Series C financing

byMillie Nelson, Editor

The word ONCOLOGY is written on wooden cubes near a stethoscope

Lilly taking sting out of Scorpion in $2.5bn cancer drug buy

Lilly taking sting out of Scorpion in $2.5bn cancer drug buy

byMillie Nelson, Editor

the word deal written on blue blocks in white writing

JPM 2025: Gilead inks inflammatory deal with LEO

JPM 2025: Gilead inks inflammatory deal with LEO

byMillie Nelson, Editor

dollar bills

JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn

JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn

byMillie Nelson, Editor

JPM written on wooden blocks in blue

JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx

JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx

byMillie Nelson, Editor

Charles River launches UK incubator program

Charles River launches UK incubator program

byMillie Nelson, Editor

Two cartoons pushing puzzle pieces together

Chroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75m

Chroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75m

byMillie Nelson, Editor

Obesity on a board

Antag bags $84M in series A funding to drive obesity candidate to the clinic

Antag bags $84M in series A funding to drive obesity candidate to the clinic

byMillie Nelson, Editor

M&A on wooden blocks

AbbVie forks out $200m to buy Roche spin-out Nimble

AbbVie forks out $200m to buy Roche spin-out Nimble

byMillie Nelson, Editor

plan prepare perform

‘Luck only comes to the most prepared people,’ says AltruBio CEO

‘Luck only comes to the most prepared people,’ says AltruBio CEO

byMillie Nelson, Editor

Trust on a dial

Three’s a crowd? Not in this partnership, says MicroFluidX

Three’s a crowd? Not in this partnership, says MicroFluidX

byMillie Nelson, Editor

Berlin on written wooden block

Bayer expands global incubator network with Germany hub

Bayer expands global incubator network with Germany hub

byMillie Nelson, Editor

Data

To protect the future of healthcare, we need to be data-driven

To protect the future of healthcare, we need to be data-driven

byMillie Nelson, Editor

The ELA'S 2024

LSX awards the crème de la crème of dealmaking

LSX awards the crème de la crème of dealmaking

byMillie Nelson, Editor

M&A note

Novartis chases muscular dystrophy treatment with Kate Tx buy

Novartis chases muscular dystrophy treatment with Kate Tx buy

byMillie Nelson, Editor

Novo Nordisk sign

Business Strategy

Lessons and blessings: The Novo Nordisk way

Lessons and blessings: The Novo Nordisk way

byMillie Nelson, Editor

A whiteboard saying transition

From Series A to B: Navigating the transition from promise to proof

From Series A to B: Navigating the transition from promise to proof

byMillie Nelson, Editor

Shaking hands

Picky pharma prone to better proven partners amid dealmaking downturn

Picky pharma prone to better proven partners amid dealmaking downturn

byMillie Nelson, Editor

coloured pencils

Nonprofit looks to bring tomorrow’s science into today’s classrooms

Nonprofit looks to bring tomorrow’s science into today’s classrooms

byMillie Nelson, Editor

Europe’s aversity to risk is why the US is ahead, say experts

Europe’s aversity to risk is why the US is ahead

byMillie Nelson, Editor

Picture with women's health written on a card in pink

Call for specific female health funding to tackle biotech finance gender gap

Call for specific female health funding to tackle biotech finance gender gap

byMillie Nelson, Editor

Alzheimer's disease written in blocks

AbbVie forks out $1.4bn to buy Alzheimer’s therapy developer Aliada

AbbVie forks out $1.4bn to buy Aliada

byMillie Nelson, Editor

What’s your secret sauce? VC’s on what makes a compelling pitch

VC’s on what makes a compelling pitch

byMillie Nelson, Editor

From east to west: Lilly plans incubators in China and UK

From east to west: Lilly plans incubators in China and UK

byMillie Nelson, Richard Daverman

Dollar notes

The rise of radiopharmaceuticals sees big pharma back Aktis’ $175m Series B

The rise of radiopharmaceuticals sees big pharma back Aktis’ $175m Series B

byMillie Nelson, Editor

Business Strategy

Build trust by making healthcare fairer and more equitable, say experts

Build trust by making healthcare fairer and more equitable, say experts

byMillie Nelson, Editor

Green leaf with sustainability symbol

Business Strategy

The sustainability series: Reflect, rethink, and reform

The sustainability series: Reflect, rethink, and reform

byMillie Nelson, Editor

Subscribe to Our Newsletters

Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.